TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Animals
Carcinoma, Hepatocellular
/ genetics
DNA-Binding Proteins
/ adverse effects
Disease Models, Animal
Gene Regulatory Networks
/ genetics
Liver Neoplasms
/ genetics
Mice
Mice, Knockout
Statistics, Nonparametric
Transcription Factors
/ adverse effects
Transcriptional Coactivator with PDZ-Binding Motif Proteins
/ adverse effects
YAP-Signaling Proteins
/ adverse effects
BCL2L12
Hepatocellular carcinoma
TAZ
YAP
c-MYC
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
02
03
2021
revised:
12
08
2021
accepted:
17
08
2021
pubmed:
1
9
2021
medline:
16
2
2022
entrez:
31
8
2021
Statut:
ppublish
Résumé
Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development. The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreER We found that the Hippo cascade is inactivated in c-Myc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In c-Myc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression. TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and c-MYC activation. The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma.
Sections du résumé
BACKGROUND & AIMS
Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development.
METHODS
The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreER
RESULTS
We found that the Hippo cascade is inactivated in c-Myc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In c-Myc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression.
CONCLUSIONS
TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and c-MYC activation.
LAY SUMMARY
The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma.
Identifiants
pubmed: 34464659
pii: S0168-8278(21)02016-X
doi: 10.1016/j.jhep.2021.08.021
pmc: PMC9569156
mid: NIHMS1821070
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
MYCBP protein, human
0
Transcription Factors
0
Transcriptional Coactivator with PDZ-Binding Motif Proteins
0
YAP-Signaling Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-134Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK026743
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204586
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239251
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250227
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Cancers (Basel). 2018 Mar 20;10(3):
pubmed: 29558384
Curr Opin Cell Biol. 2017 Dec;49:99-107
pubmed: 29316535
Gastroenterology. 2014 Sep;147(3):690-701
pubmed: 24837480
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187130
Gastroenterology. 2017 Feb;152(3):533-545
pubmed: 28003097
Genes (Basel). 2017 May 13;8(5):
pubmed: 28505071
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Int J Mol Sci. 2019 Feb 01;20(3):
pubmed: 30717258
Science. 2019 Nov 22;366(6468):1029-1034
pubmed: 31754005
Mol Cell Biol. 2008 Apr;28(7):2426-36
pubmed: 18227151
Genes Dev. 2012 Jun 15;26(12):1300-5
pubmed: 22677547
Mol Cell. 1999 Aug;4(2):199-207
pubmed: 10488335
Sci Signal. 2018 Sep 11;11(547):
pubmed: 30206136
Am J Pathol. 2014 Apr;184(4):912-923
pubmed: 24480331
Cold Spring Harb Perspect Med. 2014 Jul 01;4(7):a014407
pubmed: 24985130
J Hepatol. 2016 Apr;64(4):881-90
pubmed: 26639397
Cancer Res. 2011 Mar 15;71(6):2286-97
pubmed: 21262914
Am J Pathol. 2020 Jul;190(7):1397-1413
pubmed: 32283103
Mol Cell Biol. 2004 Oct;24(19):8541-55
pubmed: 15367674
Hepatology. 2017 Jul;66(1):167-181
pubmed: 28370287
Cell. 2012 Dec 21;151(7):1457-73
pubmed: 23245941
Gastroenterology. 2017 Nov;153(5):1378-1391.e6
pubmed: 28734833
Cell. 2007 Sep 21;130(6):1120-33
pubmed: 17889654
Cancer Res. 1993 Apr 15;53(8):1719-23
pubmed: 8467484
Cell Mol Gastroenterol Hepatol. 2021;11(4):1095-1117
pubmed: 33232824
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Nature. 2004 Oct 28;431(7012):1112-7
pubmed: 15475948
Br J Haematol. 2009 Apr;145(1):45-58
pubmed: 19183193